Dr. Noon CVD
Retina-based AI risk prediction solution that assesses future cardiovascular disease risk
Software · Cloud SaaSCompany source
Company profile
About Mediwhale
Mediwhale is an AI-powered healthcare company dedicated to developing preventive technologies that enable personalized disease management and early risk detection of major chronic diseases. The company leverages retinal imaging and artificial intelligence to establish a new standard in early detection, personalized risk assessment, and preventive care for cardiometabolic diseases. Their core mission is to empower everyone to detect health risks early through a simple eye scan in primary care settings, making this approach easy, accessible, safe, and cost-effective. Mediwhale's flagship product, Dr. Noon CVD, is the world's first regulatory-approved AI solution for cardiovascular risk assessment using retinal imaging, demonstrating predictive accuracy comparable to heart CT scans. Dr. Noon Fundus diagnoses retinal abnormalities including glaucoma, cataracts, and retinal diseases from a single retinal photograph. Built on over 2.1 million high-quality clinical data points and validated through 50+ peer-reviewed publications, Mediwhale's AI is trained across diverse populations and imaging devices. The company's solutions are commercially deployed beyond pilot stage, certified in 8 regions, and adopted by hospitals and clinics worldwide in Korea, Dubai, the UK, and Italy. Mediwhale's technology provides safe, radiation-free tests completed in minutes, offering instant, accurate results for doctors while ensuring maximum patient comfort.
Company description Mediwhale official website
Primary marketMedical Imaging & Radiology
Commercial modelCommercial information available on request
Work at Mediwhale?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- cardiovascular disease
- cataracts
- chronic kidney disease
- cognitive disorders
- glaucoma
- metabolic dysfunction associated steatotic liver disease
- retinal diseases
Who it serves
- Clinics
- Health Systems
- Hospitals
- Primary Care
Deployment & integration
Cloud Saas deployment with recorded integration context.
Geographic context
MarketsEurope · Italy · South Korea · United Arab Emirates · United Kingdom
Company sourceOfficial website
Company milestones
Platform expansion
EU CE MDR approval (May 2025), Series C funding of ₩20 billion preparing for IPO (March 2025), MICCAI 2024 1st place winner in two diabetic retinopathy categories
Partnerships
Recorded partners
- GluCare.Health
- Naeun Hospital
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Dr. Noon Fundus
Retina-based AI solution that diagnoses retinal abnormalities including glaucoma, cataracts, and retinal diseases
Software · Cloud SaaSCompany source
DrNoon (Europe)
European-certified version of Mediwhale's retinal AI solutions
Software · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
The Eye as a Window to Cardio-Kidney-Metabolic Disease.Clinical journal of the American Society of Nephrology : CJASN · Aug 19, 2026
Generative adversarial networks (GAN) for pre-dilation retinal photograph quality enhancement.Eye (London, England) · Jul 24, 2026
Waist Circumference Modifies the Association Between a Deep Learning-Derived Retinal Biomarker and Coronary Artery Calcium Score in Asymptomatic Adults.Journal of clinical medicine · Jun 19, 2026
Clinical utility of an AI-based retinal imaging model for cardiovascular risk prediction in hypertensive retinopathy.Canadian journal of ophthalmology. Journal canadien d'ophtalmologie · Jun 1, 2026
Does lens opacity matter? The effect of cataract on deep learning based cardiovascular disease risk scores from fundus photos.Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) · May 30, 2026
Retinal biological age correlates with bone mineral density and fracture risk score and predicts incident osteoporosis.PLOS digital health · May 1, 2026
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Predictive accuracy comparable to heart CT scans
cardiovascular event prediction
Early detection enabling life-saving interventions
case study of severe cardiovascular disease detected via retinal scan
GluCare.Health
Cardiovascular risk assessment as alternative to CT scans for more frequent and accessible testing
Dr. Noon CVD's AI-driven retinal scan closely aligned with CT findings, in a fraction of the time and without radiation exposure, enabling more frequent risk assessments
Naeun Hospital
Early detection of severe cardiovascular disease through retinal imaging in patient with mild eye pain symptoms
Life-saving cardiac stent placement following early detection of severe cardiovascular disease through Dr. Noon CVD
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Kevin Taegeun Choi
Chief Executive Officer, Co-founder
Tyler Hyungtaek Rim
Chief Medical Officer, Co-founder
Geunyoung Lee
Chief Technology Officer, Co-founder
Jamie Junho Oh
Head of Korea Business
Justin Sooman Kim
Head of Global Business
06 · Company updates
Updates from Mediwhale
Recent articles published on Mediwhale's official website.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Medical Imaging & Radiology
Companies that apply AI to analyze medical images for diagnostic purposes, workflow optimization, or clinical decision support. Covers general radiology (X-rays, CT scans, MRIs, ultrasounds) across multiple organ systems, as well as specialized imaging in ophthalmology and dermatology.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.